p.57 抽出テキスト
June 18/25, 2019 Circulation. 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625 e1138 CLINICAL STATEMENTS AND GUIDELINES outcomes, and health care resource utilization. J Manag Care Spec Pharm. 2014;20:677–84. S6-22. Drozda JP Jr, Ferguson TB Jr, Jneid H, et al. 2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. Circ Cardiovasc Qual Outcomes. 2016;9:68–95. S6-23. Krones T, Keller H, Sonnichsen A, et al. Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trial. Ann Fam Med. 2008;6:218–27. S6-24. ASCVD Risk Estimator Plus. Available at: http://tools.acc.org/ASCVD- Risk-Estimator-Plus/#!/calculate/estimate/. Accessed September 1, 2018. S6-25. Statin Choice Decision Aid. Available at: https://statindecisionaid. mayoclinic.org/. Accessed October 13, 2018. S6-26. Barry MJ, Edgman-Levitan S. Shared decision making–pinnacle of patient-centered care. N Engl J Med. 2012;366:780–1. S6-27. Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35:114–31. S6-28. Using Motivational Interviewing to Create Change. Available at: http:// pharmacistsletter.therapeuticresearch.com/(X(1)S(0wvsds30 xqejdo551cdariq1))/ce/cecourse.aspx?pc=12–243&AspxAutoDetec tCookieSupport=1. Accessed March 27, 2018. 7 COST AND VALUE CONSIDERATIONS 7.1 Economic Value Considerations: PCSK9 Inhibitors S7.1-1. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA state- ment on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129:2329–45. S7.1-2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clini- cal outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. S7.1-3. Hlatky MA, Kazi DS. PCSK9 Inhibitors: economics and policy. J Am Coll Cardiol. 2017;70:2677–87. S7.1-4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78. S7.1-5. Fonarow GC, Keech AC, Pedersen TR, et al. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2:1069–78. S7.1-6. Robinson JG, Huijgen R, Ray K, et al. Determining when to add nonstatin therapy: a quantitative approach. J Am Coll Cardiol. 2016;68:2412–21. S7.1-7. Kazi DS, Moran AE, Coxson PG, et al. Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesaaaaaaaaterolemia or atherosclerotic cardiovascular disease. JAMA. 2016;316:743–53. S7.1-8. Gandra SR, Villa G, Fonarow GC, et al. Cost-effectiveness of LDL-C lowering with evolocumab in patients with high cardiovascular risk in the United States. Clin Cardiol. 2016;39:313–20. S7.1-9. Choosing interventions that are cost effective (WHO-CHOICE): cost-effectiveness thresholds. Geneva, Switzerland: World Health Organization, 2009. 8 LIMITATIONS AND KNOWLEDGE GAPS 8.2 Risk Assessment S8.2-1. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S1–45. Downloaded from http://ahajournals.org by on October 7, 2026